Precision Bioservices, Inc.

Precision BioSciences is a biotechnology company developing genome editing medicines using its proprietary ARCUS platform, which uses DNA-cutting enzymes to insert, remove, or repair DNA in living cells and tissues. The company's pipeline includes clinical-stage programs targeting rare genetic diseases, including PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.